About Ascendance Biotechnology
Ascendance Biotechnology is a company based in Medford (United States) founded in 2015 was acquired by BioIVT in March 2018. Ascendance Biotechnology has raised $880 thousand across 2 funding rounds from investors including BioIVT. The company has 11 employees as of December 31, 2017. Ascendance Biotechnology operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Medford, United States
- Employees 11 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ascendance Biotechnology
Ascendance Biotechnology has successfully raised a total of $880K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $230 thousand completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ascendance Biotechnology
Ascendance Biotechnology has secured backing from 1 investor. Prominent investors backing the company include BioIVT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of in vitro diagnostic products and assay services
|
Locked | Locked | Locked |
Investor details for Ascendance Biotechnology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ascendance Biotechnology
Investment portfolio details for Ascendance Biotechnology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ascendance Biotechnology
Detailed financials for Ascendance Biotechnology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ascendance Biotechnology Comparisons
Peer comparison for Ascendance Biotechnology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ascendance Biotechnology
Ascendance Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
Detailed competitors of Ascendance Biotechnology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ascendance Biotechnology
Complete news archive for Ascendance Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ascendance Biotechnology
Ascendance Biotechnology was founded in 2015.
Ascendance Biotechnology is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.
Ascendance Biotechnology is a funded company, having raised a total of $880K across 2 funding rounds to date.
As of Dec 31, 2017, the latest employee count at Ascendance Biotechnology is 11.
Ascendance Biotechnology was established in 2015 through the consolidation of assets from Hepregen Corporation and ESI BIO, operating as a transnational entity in the biotechnology sector. Cell-based assay products, including HepatoPac and HepatoMune micro-liver platforms, are manufactured in Medford, United States, alongside contract services for pharmaceutical and diagnostic applications. Stem cell lines, progenitor cells, hydrogel kits, antibodies, and small molecules from the ESI BIO line are also distributed.
Ascendance Biotechnology's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Ascendance Biotechnology has 1 investor. Key investors include BioIVT.